List of Tables:

TABLE 1 U.S. UTERINE FIBROID MARKET, BY TYPE, 2013-2022 (USD Million)
TABLE 2 U.S. UTERINE FIBROID MARKET, BY DIAGNOSIS, 2013-2022 (USD Million)
TABLE 3 U.S. UTERINE FIBROID MARKET, BY TREATMENT, 2013-2022 (USD Million)
TABLE 4 U.S. UTERINE FIBROID MARKET, BY TREATMENT TYPE, 2013-2022 (USD Million)
TABLE 5 PIPELINE PRODUCTS FOR UTERINE FIBROIDS
TABLE 6 ASTRAZENECA: KEY DEVELOPMENT
TABLE 7 BOSTON SCIENTIFIC CORPORATION: KEY DEVELOPMENT
TABLE 8 GE HEALTHCARE: KEY DEVELOPMENT
TABLE 9 ABBVIE INC.: KEY DEVELOPMENT
TABLE 10 HOLOGIC INC.: KEY DEVELOPMENT

LIST OF FIGURE

List of Figures:

FIGURE 1 COMPARISON BETWEEN DIAGNOSIS & TREATMENT MARKET, 2013-2022 (USD Million)
FIGURE 2 U.S. UTERINE FIBROID MARKET: MARKET STRUCTURE
FIGURE 3 RESEARCH PROCESS
FIGURE 4 U.S. UTERINE FIBROID MARKET, BY TYPE, 2015 & 2022 (USD Million)
FIGURE 5 U.S. UTERINE FIBROID MARKET, BY DIAGNOSIS, 2015 & 2022 (USD Million)
FIGURE 6 TREATMENTS FOR UTERINE FIBROIDS
FIGURE 7 U.S. UTERINE FIBROID MARKET, BY TREATMENT, 2013-2022 (USD Million)
FIGURE 8 U.S. UTERINE FIBROID MARKET, BY TREATMENT TYPE, 2015 & 2022 (USD Million)
FIGURE 9 PHARMACOTHERAPY TREATMENT FORECAST, 2015-2022
FIGURE 10 ASTRAZENECA: RECENT FINANCIAL
FIGURE 11 ASTRAZENECA: GEOGRAPHICAL MIX
FIGURE 12 ASTRAZENECA: OPERATING SEGMENTS
FIGURE 13 ASTRAZENECA: SWOT ANALYSIS
FIGURE 14 BOSTON SCIENTIFIC CORPORATION: RECENT FINANCIAL
FIGURE 15 BOSTON SCIENTIFIC CORPORATION: RECENT FINANCIAL
FIGURE 16 BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS
FIGURE 17 GE HEALTHCARE: RECENT FINANCIAL
FIGURE 18 GE HEALTHCARE: GEOGRAPHICAL MIX
FIGURE 19 GE HEALTHCARE: OPERATING SEGMENTS
FIGURE 20 GE HEALTHCARE: SWOT ANALYSIS
FIGURE 21 ABBVIE INC.: RECENT FINANCIAL
FIGURE 22 ABBVIE INC.: GEOGRAPHICAL MIX
FIGURE 23 ABBVIE INC: OPERATING SEGMENTS
FIGURE 24 ABBVIE INC.: SWOT ANALYSIS
FIGURE 25 HOLOGIC INC.: RECENT FINANCIAL
FIGURE 26 HOLOGIC INC: GEOGRAPHICAL MIX
FIGURE 27 HOLOGIC INC: OPERATING SEGMENTS
FIGURE 28 HOLOGIC INC.: SWOT ANALYSIS